Pirtobrutinib
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Lymphocytic Leukemia
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Timeline
Jan 3, 2025 → Dec 1, 2028
NCT ID
NCT06588478About Pirtobrutinib
Pirtobrutinib is a phase 2 stage product being developed by Eli Lilly for Chronic Lymphocytic Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06588478. Target conditions include Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05172700 | Pre-clinical | Completed |
| NCT07162181 | Phase 2 | Recruiting |
| NCT06876662 | Approved | Recruiting |
| NCT06876649 | Approved | Recruiting |
| NCT06812715 | Phase 2 | Recruiting |
| NCT06588478 | Phase 2 | Recruiting |
| NCT06258174 | Phase 1 | Completed |
| NCT06190678 | Phase 1 | Completed |
| NCT06180980 | Phase 1 | Completed |
| NCT06190691 | Phase 1 | Completed |
| NCT06181006 | Phase 1 | Completed |
Competing Products
20 competing products in Chronic Lymphocytic Leukemia